AJJ Medtech Holdings Limited: Financial Report Analysis
Net Profit Decline: 53% YoY (FY2024 vs FY2023)
Business Description
AJJ Medtech Holdings Limited (the “Company”) is a Singapore-based company engaged in the business of [insert business description]. However, the exact business description is not provided in the report.
Key Facts and Figures
The Company reported a loss after tax of S$3,865,000 for the financial year ended 31 December 2024 (FY2024), compared to a loss after tax of S$2,527,000 in the previous year.
The Group incurred net operating cash outflows of S$1,662,000 in FY2024, compared to S$1,785,000 in the previous year.
As of 31 December 2024, the Group has net liabilities of S$1,426,000 and net current liabilities of S$1,121,000.
Financial Performance
Income Statement
Revenue: Not disclosed
Net Profit: S$3,865,000 loss (FY2024) vs S$2,527,000 loss (FY2023)
Balance Sheet
Total Assets: Not disclosed
Total Liabilities: Not disclosed
Net Assets: S$1,426,000 (net liabilities) (FY2024)
Cash Flow Statement
Net Operating Cash Outflows: S$1,662,000 (FY2024)
Key Risks and Concerns
The Group’s ability to continue as a going concern is uncertain due to its net liabilities and net operating cash outflows.
The Company is dependent on the support of its director and controlling shareholder, Dr. Zhang Jian, who has provided additional loans to the Company.
Recommendations
For current investors:
Hold or sell the stock with caution, considering the uncertainty surrounding the Company’s ability to continue as a going concern.
For potential investors:
Exercise caution when investing in the Company, given the above-mentioned risks and concerns.
Disclaimer: The recommendation is based solely on the information provided in the report and may not reflect the current market situation or future performance of the Company. Investors should conduct their own research and consult with financial advisors before making any investment decisions.
Date of Report and Financial Year
Date of Report: 15 April 2025
Financial Year: Year ended 31 December 2024 (FY2024)
Special Activities or Actions
The Company is taking measures to improve its profitability, including:
Dr. Zhang Jian, the director and controlling shareholder, has provided additional loans to the Company.
The Company has obtained written undertakings from its executive directors and independent directors to defer the payment of their salaries and other balances owed to them.

Key Financial Highlights:

• Loss After Tax: S\$3,865,000 loss (FY2024) vs S\$2,527,000 loss (FY2023) – 53% YoY decline
• Net Operating Cash Outflows: S\$1,662,000 (FY2024) vs S\$1,785,000 (FY2023)
• Net Liabilities: S\$1,426,000 (FY2024)

View AJJ Medtech Historical chart here